Ranbaxy reportedly near $100M generics deal
India's Ranbaxy Laboratories is reportedly close to buying the Russian generic drug company Akrikhin for about $100 million. The Business Standard reported that Ranbaxy was looking to expand its presence in the Russian market. If it completes the deal it will mark the latest in a string of acquisitions in Italy, Spain, Romania and Belgium. Ranbaxy has been scouting the Canadian market as well.
- check out this report on Ranbaxy
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
